Sector ratings Arrowhead Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 20/04/2026 BST			5-day change	1st Jan Change
69.25 ^USD	-0.37%		+8.56%	+4.31%

03-28	Arrowhead Pharmaceuticals Presents New Long-Term Efficacy And Safety Data For Plozasiran Across A Spectrum Of Hypertriglyceridemia	CI
03-25	Sarepta Therapeutics Announces First Clinical Data from Sirna Pipeline Targeting FSHD1 and DM1	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation	Visibility
ARROWHEAD PHARMACEUTICALS, INC.	9.73B	-	BB	-	-
ARGENX SE	52.7B		A
WUXI APPTEC CO., LTD.	44.07B		AAA
INSMED INCORPORATED	31.19B	-	A	-	-
BIONTECH SE	26.03B	-	-	-	-
SUMMIT THERAPEUTICS INC.	19.5B	-	-	-	-
WUXI BIOLOGICS (CAYMAN) INC.	18.88B		AAA
AKESO, INC.	17.76B		B		-
GENMAB A/S	17.49B		A
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	15.49B	-	AA	-	-
MADRIGAL PHARMACEUTICALS, INC.	12.2B	-	B	-	-
EXELIXIS, INC.	11.66B		BB
REMEGEN CO., LTD.	10.96B		-
SAMSUNG EPIS HOLDINGS CO., LTD.	10.07B		-			-
VAXCYTE, INC.	8.97B	-	BBB	-	-
NUVALENT, INC.	8.46B	-	CCC	-	-
CYTOKINETICS, INCORPORATED	8.22B	-	AA	-	-
IMMUNITYBIO, INC.	7.95B	-	CCC	-	-
PHARMAESSENTIA CORPORATION	7.71B		AA
BELITE BIO, INC	6.51B	-	-	-	-
Average	17.28B		A
Weighted average by Cap.			A